Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3214487 | 0.81 | MEN1 (0.54) | ALDH1A1HSD17B10TUBB1ERN1MAPT | |
| SCHEMBL8421788 | 0.81 | ERN1 (0.65) | TUBB1ERN1TRIM24TYRTRIM33 | |
| SCHEMBL662439 | 0.81 | KDM4E (0.46) | ALDH1A1TUBB1ERN1APPMAPT | |
| SCHEMBL2204435 | 0.79 | ERN1 (0.61) | ALDH1A1ERN1MAPTSMN1; SMN2TRIM24 | |
| SCHEMBL5960246 | 0.79 | NR4A1 (0.50) | ALDH1A1CASP1CASP7HSD17B10CHEK2 | |
| SCHEMBL11480200 | 0.79 | KDM4E (0.44) | ALDH1A1CASP1CASP7HSD17B10TUBB1 | |
| SCHEMBL3204682 | 0.77 | TYR (0.65) | ALDH1A1TUBB1ERN1APPMAPT | |
| SCHEMBL5143351 | 0.77 | ALDH1A1 (0.67) | ALDH1A1TUBB1ERN1MAPTHPGD | |
| SCHEMBL16741184 | 0.77 | APP (0.41) | ALDH1A1ERN1APPTRIM24TYR | |
| SCHEMBL3782428 | 0.76 | TUBB1 (0.49) | ALDH1A1TUBB1ERN1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-1917245-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007022946-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | ALDH1A1 1897/4885CASP1 3653/4885CASP7 3648/4885 |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | ALDH1A1 1897/4885CASP1 3653/4885CASP7 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.